Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
5 Years : From Sep 2012 to Sep 2017
Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced a proposed dividend of 15 cents per ADR.
In 2011, Trinity announced the commencement of an annual dividend policy and paid a dividend of 10 cents per ADR. This year the Company is proposing a dividend of 15 cents per ADR, representing an increase of 50%. The payment of this dividend is subject to shareholder approval, which will be sought at the Company's forthcoming AGM to be held on May 25, 2012. Subject to this approval being granted, the record date will be June 8, 2012 and payment will follow 2 weeks later.
Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
The Trinity Biotech plc logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10602
CONTACT: Trinity Biotech plc
Lytham Partners LLC
Joe Diaz, Joe Dorame & Robert Blum